Emmaus Life Sciences, Inc. announced that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari in the Kingdom of Bahrain. Endari is approved in the U.S., the United Arab Emirates, Israel, Kuwait, the State of Qatar and Bahrain to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 USD | 0.00% | +8.58% | -0.10% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.10% | 6.18M | |
+2.17% | 42.75B | |
+47.64% | 41.61B | |
+12.11% | 41.34B | |
-12.36% | 26.59B | |
+8.10% | 25.49B | |
-22.99% | 18.12B | |
+30.64% | 12.24B | |
-1.46% | 11.76B | |
+8.47% | 11B |
- Stock Market
- Equities
- EMMA Stock
- News Emmaus Life Sciences, Inc.
- Emmaus Life Sciences, Inc. Receives Medicine Registration Certificate from the Bahrain National Health Regulatory Authority